Skip to content

Study · Animal study (in vivo) · syrian hamster · 2025

2 results

Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.

Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL

Neuropharmacology9 Jan 2025Cited by 4 (Europe PMC)

PMID39793696 (opens in a new tab)PMCIDPMC12880176 (opens in a new tab)DOI10.1016/j.neuropharm.2025.110299 (opens in a new tab)PepBankPUB-39793696
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In female Syrian hamsters, neither the low nor the high dose of bremelanotide changed melanocortin receptor mRNA expression in the mesolimbic dopamine system.

    In plain wordsIn female hamsters, bremelanotide at low or high dose did not change the amount of melanocortin receptor messenger RNA in the brain reward system.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeMelanocortin receptor mRNA expression in mesolimbic dopamine system
    Study

    Syrian hamstern: not reported in source

    Female Syrian hamster
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    low and high doseAs given in this study (Syrian hamster).

    Source sentences

    Summary
    Neither the low nor the high dose of bremelanotide had an effect on the expression of melanocortin receptor mRNA in the mesolimbic dopamine system.
    1 context sentence
    Summary · context
    In this study, we utilized a female Syrian hamster model to investigate the effects of bremelanotide on melanocortin receptor expression in the mesolimbic dopamine system and sexual reward.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female Syrian hamsters, bremelanotide treatment did not enhance sexual reward in the conditioned place preference test.

    In plain wordsIn female hamsters, bremelanotide did not make the reward from sexual experience stronger in a place preference test.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeSexual reward in conditioned place preference
    Study

    Syrian hamstern: not reported in source

    Female Syrian hamster
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    low and high doseAs given in this study (Syrian hamster).

    Source sentences

    Summary
    though bremelanotide treatment failed to enhance sexual reward in this test.
    1 context sentence
    Summary · context
    In this study, we utilized a female Syrian hamster model to investigate the effects of bremelanotide on melanocortin receptor expression in the mesolimbic dopamine system and sexual reward.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.